Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

NCT03228940 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Changed development priorities

Conditions

Interventions

Sponsor

Resverlogix Corp